Teva and Mylan settle Copaxone patent litigation in Europe
Drugmakers Teva and Mylan Inc have agreed to settle and dismiss pending patent litigation involving Teva's branded Copaxone product in the UK, France and the Netherlands.
The case between the companies concerned Teva's European Patent 762,888, which is due to expire in May 2015. All terms of the settlement are confidential.
Copaxone is used to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
In October, Teva enjoyed a court victory at the District Court of the Hague, which found that generic drugs company Mylan’s motion to the revoke the Copaxone patent was invalid. This followed a similar ruling by the English Court of Appeal in July.
In a statement at the time, Teva said that given the complexity of the drug, “unpredictable differences between a proposed generic product and Copaxone could lead to immunogenic effects in patients”.
Teva told LSIPR that it has no further comment on the settlement.
When contacted by LSIPR, Mylan did not respond to a request for comment.
